Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
HH3806
i
Other names:
HH3806
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
HaiHe Biopharma
Drug class:
BRD4 inhibitor
Related drugs:
‹
OTX015 (10)
BI2536 (3)
SRA515 (3)
GS-626510 (2)
I-BET151 (2)
PLX51107 (2)
SRX3262 (1)
ARV-825 (0)
NEO1132 (0)
NHWD-870 (0)
NUV-868 (0)
OPN-2853 (0)
PH-3861 (0)
PH-894 (0)
SF1126 (0)
SF2523 (0)
SF2535 (0)
SRX3177 (0)
OTX015 (10)
BI2536 (3)
SRA515 (3)
GS-626510 (2)
I-BET151 (2)
PLX51107 (2)
SRX3262 (1)
ARV-825 (0)
NEO1132 (0)
NHWD-870 (0)
NUV-868 (0)
OPN-2853 (0)
PH-3861 (0)
PH-894 (0)
SF1126 (0)
SF2523 (0)
SF2535 (0)
SRX3177 (0)
›
Associations
News
Trials
Filter by
Latest
over1year
A First-in-Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients With Advanced Tumors (ACTRN12622001339741)
P1, N=36, Recruiting, Tigermed Australia Pty Ltd | Initiation date: Mar 2000 --> Mar 2023
over 1 year ago
Trial initiation date • Metastases
|
HH3806
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login